US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

1.920 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elicio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout ↗
Via Chartmill
News headline image
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
From Elicio Therapeutics Inc.
Via GlobeNewswire
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Here are the top movers in Thursday's session. ↗
Via Chartmill
Top movers in Thursday's session ↗
Via Chartmill
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
From Pomerantz LLP
Via GlobeNewswire
News headline image
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
ELTX Investors Have Opportunity to Join Elicio Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc. - ELTX
From Pomerantz LLP
Via GlobeNewswire
These stocks have an unusual volume in today's session ↗
Via Chartmill
Which stocks have an unusual volume on Thursday? ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
Which stocks are moving after the closing bell on Wednesday? ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Monday's session: top gainers and losers ↗
Via Chartmill
Gapping stocks in Monday's session ↗
Via Chartmill
Monday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
News headline image
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
Preclinical data demonstrate robust T cell activation, durable immune memory, and lymph node-targeted mechanism supporting next-generation immunotherapies 
From Elicio Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >